Medical uses:

Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager used to treat adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Note: This conditional approval is based on the response rate. Ongoing studies aim to further establish the efficacy of this medication.

Recommended Dosage:

• Premedication: Prior to each dose in Cycles 1 and 2, premedicate to reduce the risk of cytokine release syndrome (CRS) and infusion-related reactions.
• Administration: Administer only as an intravenous (IV) infusion. Each cycle lasts 21 days.

Dosage Regimen:

• Cycle 1:
  • Day 1: 1 mg IV over at least 4 hours.
  • Day 8: 2 mg IV over at least 4 hours.
  • Day 15: 60 mg IV over at least 4 hours.
• Cycle 2:
  • Day 1: 60 mg IV over 2 hours if Cycle 1 was well-tolerated.
• Cycle 3 and subsequent cycles:
  • Day 1: 30 mg IV over 2 hours if Cycle 1 was well-tolerated.

Treatment Duration:

• Continue for 8 cycles unless the patient experiences unacceptable toxicity or disease progression.
• For patients achieving a complete response, no further treatment beyond 8 cycles is required.
• For those with a partial response or stable disease after 8 cycles, an additional 9 cycles (totaling 17 cycles) may be administered, unless there is unacceptable toxicity or disease progression.

Warning & Precautions

            Lunsumio Treatment Considerations:

• Cytokine Release Syndrome (CRS): Lunsumio can cause CRS, including serious or life-threatening reactions. Patients experiencing CRS or other side effects that impair consciousness should be evaluated and advised not to drive or operate machinery until symptoms resolve.
• Neurologic Toxicity: Mosunetuzumab therapy can lead to serious neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Patients should be assessed for neurologic toxicity during treatment. At the first sign of neurologic issues, including ICANS, promptly evaluate the patient and consider a neurology consultation if necessary.
• Infections: Lunsumio 1 mg/30 mg can cause severe or fatal infections. Monitor patients for signs and symptoms of infection before and throughout treatment, and treat infections promptly. Do not use Lunsumio in patients with active infections.
• Cytopenias: Lunsumio can cause severe cytopenias, including anemia, neutropenia, and thrombocytopenia. Monitor complete blood counts (CBC) throughout therapy. Depending on the severity of cytopenias, treatment may need to be temporarily interrupted or permanently discontinued.
• Tumor Flare: Lunsumio can cause significant tumor flare. Patients with bulky tumors near airways or vital organs should be closely monitored during initial therapy. Watch for signs of compression or obstruction due to tumor flare.
• Pregnancy: Based on its mechanism of action, Lunsumio may cause fetal harm if administered to a pregnant woman. Women of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.

Documentation & Availability :

Documents  required to import Lunsumio (Mosunetuzumab-axgb) to India? 

Lunsumio (Mosunetuzumab-axgb) can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:

1. 2 ID proofs along with PAN card details along with attested scanned copies
2. Valid doctor prescription scanned copy
3. Doctor’s MCI number
4. Doctor’s mobile number
5. Patients diagnostic reports

How is the order confirmed? 

The order will be confirmed only after the receipt of:

1. The above-mentioned documents and drug availability.
2. Import permit if applicable.

Sourcing & Delivery:

The Rx4U team has extensive experience in sourcing Lunsumio (Mosunetuzumab-axgb)from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.

 FAQ:

What is the Generic Name for the trade name drug Lunsumio®?

The generic name for Lunsumio® is mosunetuzumab-axgb.

What is the Manufacturer’s Name of Lunsumio®?

Lunsumio® is manufactured by Genentech, Inc.

Is Lunsumio® approved by the FDA?

Yes, Lunsumio® was approved by the FDA on December 22, 2022.

Where can I get Lunsumio® at the best price in India?

To find the best price for Lunsumio® in India, you can contact the Rx4u team. A medical prescription from a treating physician is required.

What is the dosage and form of Lunsumio® supplied?

Lunsumio® is available as injections: 1 mg/mL and 30 mg/30 mL (1 mg/mL) solution in a single-dose vial for intravenous administration.

What are the most common side effects of Lunsumio®?

The most common side effects include rash, cytokine release syndrome, pyrexia, fatigue, and headache.

How much does Lunsumio® cost in India?

The cost of Lunsumio® in India can vary. To legally procure this medication for follicular lymphoma, you can order the drug on https://rx4u.in/

What are the storage conditions of Lunsumio®?

Store Lunsumio® refrigerated at 2-8°C (36-46°F) in the original carton to protect it from light. Do not freeze or shake it.

Is it safe to buy Lunsumio® online in India?

Yes, you can safely buy Lunsumio® online in India at the lowest price from Rx4u. They can help facilitate the supply through legal channels.

*Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.